Following the APLS buyout, SLNO is a prime acquisition target with a monopoly in its indication after a competitor's drug was halted, trading at a low enterprise value relative to its projected free cash flow.
Following the APLS buyout, SLNO is a prime acquisition target with a monopoly in its indication after a competitor's drug was halted, trading at a low enterprise value relative to its projected free cash flow.